Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Andrea Bezjak(Princess Margaret Cancer Centre), Frances A. Shepherd(Princess Margaret Hospital), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), David Fenton(Ontario Institute for Cancer Research), Alexandra Gerogianni(Ontario Institute for Cancer Research), Lesley Seymour(Ontario Institute for Cancer Research), Martin Reck(LungenClinic Grosshansdorf), S. Lago(Ontario Institute for Cancer Research), Joseph Ayoub(Ontario Institute for Cancer Research), Dongsheng Tu(Ontario Institute for Cancer Research), Aleksandra Trajković(Ontario Institute for Cancer Research), Gary M. Clark(Ontario Institute for Cancer Research), Raymond Tsz‐Tong Chan(Ontario Institute for Cancer Research), Jonathan Noble(Ontario Institute for Cancer Research), Arnold Cyjon(Ontario Institute for Cancer Research), Mauro Zukin(Heidelberg University), Ronaldo de Albuquerque Ribeiro(Ontario Institute for Cancer Research), Francis Laberge(Ontario Institute for Cancer Research)
Cited by 295
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k